Management of Psoriasis
Karger Medical and Scientific Publishers, 2009 - Medical - 195 pages
Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Clinical Spectrum and Severity of Psoriasis
Impact of Comorbidities on the Management of Psoriasis
Topical Treatment of Psoriasis
Practice of Phototherapy in the Treatment of ModeratetoSevere Psoriasis
Retinoids Methotrexate and Cyclosporine
Monitoring Patients Treated with Efalizumab or Alefacept
Management of Severe Psoriasis with TNF Antagonists
Acad Dermatol acitretin active adalimumab alefacept antipsoriatic Arch Dermatol assessment associated betamethasone biological calcipotriol cells childhood psoriasis chronic plaque psoriasis Clin clinical trials combination comorbidities compared corticosteroids Crohn’s disease cutaneous cyclosporine cytokines Dermatology dithranol dosage dose double-blind drug efalizumab efficacy erythema erythrodermic etanercept etretinate form of psoriasis guttate psoriasis hepatitis improvement increased risk infection inflammatory infliximab infusion reactions involvement keratinocytes Lebwohl lesions long-term lymphoma management of psoriasis ment Menter metabolic syndrome methotrexate moderate to severe monitoring NB-UVB obesity ointment PASI 75 patients receiving patients treated patients with psoriasis Pediatr phototherapy placebo placebo-controlled protein psoriasis patients psoriatic arthritis pustular psoriasis PUVA randomized receptor response retinoids rheumatoid arthritis riasis risk factors safety scalp psoriasis severe psoriasis side effects systemic therapy tacrolimus tazarotene therapeutic tion TNF antagonists topical corticosteroids topical therapy treatment of psoriasis UVB phototherapy vitamin D vitamin D analogue vitamin D3